1. 347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial. (10th December 2020) Authors: Winer, Ira; Gilbert, Lucy; Vaishampayan, Ulka; Rosen, Seth; Hoimes, Christopher; Muzaffar, Jameel; Spreafico, Anna; McDermott, David; Chu, Quincy; Dumas, Olivier; Chauhan, Aman; Chaudhry, Arvind; Tomczak, Piotr; Boni, Valentina; Bruno, Debora; Curtis, Kelly; Wang, Yan; Dorn, Elizabeth; Rege, Jess... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2. (10th December 2020) Authors: Powderly, John; Carthon, Bradley; Ernstoff, Marc; Olszanski, Anthony; Wrangle, John; Shields, Anthony; Piha-Paul, Sarina; Curtis, Kelly; Bidollari, Ilda; Du, Yangchun; Sun, Lei; Putiri, Emily; Wang, Yan; Losey, Heather; Dezube, Bruce; Dezube, Bruce; Vaishampayan, Ulka Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2. (9th November 2020) Authors: Powderly, John; Carthon, Bradley; Ernstoff, Marc; Olszanski, Anthony; Wrangle, John; Shields, Anthony; Piha-Paul, Sarina; Curtis, Kelly; Bidollari, Ilda; Du, Yangchun; Sun, Lei; Putiri, Emily; Wang, Yan; Losey, Heather; Dezube, Bruce; Dezube, Bruce; Vaishampayan, Ulka Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A398 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗